空間基因組學和轉錄組學市場：策略性洞察與預測（2026-2031 年）

Spatial Genomics and Transcriptomics Market - Strategic Insights and Forecasts (2026-2031)

出版日期: 2026年08月19日 | 出版商:

Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計空間基因組學和轉錄組學市場將以 11.87% 的複合年成長率成長，從 2025 年的 732,413,000 美元成長到 2031 年的 1,435,830,000 美元。

太空基因組學和轉錄組學市場正經歷重大變革，其驅動力包括：利用空間資訊的藥物研發項目不斷擴展、大規模人類細胞圖譜舉措的推進，以及生物標記開發在腫瘤學領域日益成長的重要性。這一市場演變的特點在於，人們越來越認知到空間生物學在連接分子活性與組織結構方面發揮著至關重要的作用，使研究人員能夠理解傳統定序方法無法捕捉到的細胞間相互作用、疾病微環境和治療反應機制。製藥公司研發投入、國家圖譜計畫以及計算生物學的進步正在重塑研究人員進行組織層面疾病表徵的方式。製藥公司越來越需要能夠同時捕捉細胞狀態和組織結構的分子訊息，尤其是在免疫腫瘤學、細胞療法和精準醫療計畫中。美國國立衛生研究院 (NIH) 的腦部舉措細胞圖譜網路 (BICAN) 正在支援一系列項目，預計未來五年每年將投入約 1 億美元，這將持續推動對空間定序、成像、運算分析及相關耗材的需求。在這個市場中，大量投資正湧入整合空間生物學生態系統、多組學體學和人工智慧驅動的數據解讀領域，而空間基因組學和轉錄組學正逐漸成為轉化研究、生物標記發現和精準醫療開發中的策略要素。

市場促進因素

利用空間資訊進行藥物研發計畫的擴展是空間基因組學和轉錄組學市場的主要驅動力。製藥公司越來越需要能夠同時捕捉細胞狀態和組織結構的分子訊息。免疫腫瘤學、細胞療法和精準醫療計畫通常依賴對免疫細胞、基質細胞和癌細胞在疾病微環境中相互作用的理解。空間生物學平台能夠提供此類信息，幫助研究人員識別傳統定序方法無法揭示的生物標記和治療反應機制。企業對試劑生產和平台擴展的投資表明，製藥業的需求預計將持續成長。此外，在藥物研發經費分配中，對具有高空間解析度的多體學學資料集的重視程度也日益提高。
大規模人類細胞圖譜舉措的擴展是另一個重要的成長要素。國內外的圖譜計畫正在創建高空間解析度的人體組織、器官和疾病狀態圖譜。諸如BICAN和HuBMAP之類的計畫正在產生數千個涵蓋多個器官和供體的資料集。這些舉措需要高通量定序、先進的成像系統、計算基礎設施和長期數據管理能力。產生的資料集也為尋求用於比較研究的參考材料的研究人員創造了二次需求。 HuBMAP在其入口網站資料集中產生了涵蓋27個器官類別和310名註冊供體的5032個資料集，對空間資料產生的需求正在顯著成長。
生物標記開發在腫瘤學領域的重要性日益凸顯，加速了太空技術的應用。由於腫瘤生物學高度依賴組織環境，癌症仍然是太空技術最具商業應用前景的領域之一。製藥公司正日益尋求能夠揭示免疫細胞定位、腫瘤異質性和治療反應路徑的生物標記。空間轉錄組學和多重成像技術能夠提供訊息，支持患者篩選和轉化研究。平台提供者對多組學工作流程的投資，反映出腫瘤學研究在推動採購方面的作用日益增強。癌症體學的上升以及對精準治療模式的需求，正在推動對空間分析的需求。
轉錄組學、基因組學和蛋白質組學工作流程的整合正在拓展空間生物學平台的潛在市場。研究機構正從單一分析方法轉向結合多個分子層次的多體學方法。在太空生物學平台領域，將RNA、DNA和蛋白質測量整合到單一工作流程的趨勢正在加速發展。其商業性優勢在於減少實驗碎片化，同時產生更豐富的資料集。供應商正透過夥伴關係、收購和平台整合策略來因應這一趨勢，旨在獲取更大的研究經費佔有率。
計算生物學和人工智慧的進步正在提升空間資料集的效用。空間生物學的價值很大程度取決於對數據的解讀。機器學習、影像分析和多模態資料整合技術的進步進一步增強了空間資料集的效用。研究活動日益集中於建立基礎模型和分析框架，以便從日益複雜的資料集中提取生物學見解。隨著分析能力的提升，太空實驗的投資報酬率對製藥公司和學術機構的吸引力也越來越大。 HuBMAP的視覺化工具提供了超過1500個空間資料集，這推動了對軟體和解讀平台的需求。

市場限制因素

設備和工作流程的高成本對學術機構和小規模研究組織構成預算限制。空間基因組學和轉錄組學平台通常需要大量的資本投入。除了購置設備外，實驗室還必須購買專用試劑、定序設備、軟體許可、資料儲存基礎設備和分析支援。學術機構的預算限制和研究經費的波動可能會延遲採購決策。據業內相關人員，資本投資壓力仍是部分客戶群面臨的挑戰。
數據解讀的複雜性限制了技術的應用，並增加了對專業知識的依賴。對許多實驗室而言，產生空間資料已不再是主要挑戰。解讀高維度資料集通常需要生物資訊學、影像分析、計算生物學和統計學方面的專業知識。這些領域的人才短缺會導致技術應用的延遲。當基因組、轉錄組和蛋白質組數據整合到同一工作流程中時，複雜性會進一步增加。
工作流程缺乏標準化使得不同研究之間的比較和檢驗變得複雜。目前市場上有許多技術方案，包括基於定序、基於探針、基於成像和原位雜合反應的平台。樣本製備、空間解析度、通量和分析流程的差異會導致研究間比較困難。這種碎片化可能會提高檢驗要求，並延緩在監管嚴格的環境中推廣應用。
從研究應用到臨床部署的漫長過程導致商業化所需時間延長。許多空間基因組學和轉錄組學技術仍主要集中在研究領域。臨床部署需要進行分析檢驗、監管審查、可重複性測試以及臨床效用論證。這些流程會延長商業化時間並增加研發成本。對於旨在拓展診斷應用領域的供應商而言，這項挑戰尤其嚴峻。
智慧財產權和競爭給新興供應商帶來了不確定性。該領域智慧財產權活動活躍，各公司都在努力保護檢測、成像技術和分析方法的化學機制。專利糾紛和許可要求會增加營運成本，並給新興供應商帶來不確定性。擁有成熟專利組合的大公司在新技術商業化方面可能具有優勢。

The spatial genomics and transcriptomics market is undergoing significant transformation driven by the expansion of spatially informed drug discovery programs, growth of large-scale human cell atlas initiatives, and the rising importance of oncology biomarker development. The market's evolution is characterized by the growing recognition that spatial biology provides essential capabilities for linking molecular activity to tissue architecture, enabling researchers to understand cellular interactions, disease microenvironments, and treatment-response mechanisms that remain invisible through conventional sequencing approaches. The convergence of pharmaceutical R&D investment, national atlas projects, and computational biology advances is reshaping how researchers approach tissue-level disease characterization. Drug developers increasingly require molecular information that captures both cellular state and tissue organization, particularly in immuno-oncology, cell therapy, and precision medicine programs. The U.S. National Institutes of Health's BRAIN Initiative Cell Atlas Network (BICAN) supports projects expected to total approximately USD 100 million annually over five years, creating sustained demand for spatial sequencing, imaging, computational analysis, and associated consumables. The market is witnessing significant investment in integrated spatial biology ecosystems, multiomic workflows, and AI-driven data interpretation, positioning spatial genomics and transcriptomics as a strategic component within translational research, biomarker discovery, and precision medicine development.

Market Drivers

The expansion of spatially informed drug discovery programs represents the primary driver for the spatial genomics and transcriptomics market. Drug developers increasingly require molecular information that captures both cellular state and tissue organization. Immuno-oncology, cell therapy, and precision medicine programs often depend on understanding how immune cells, stromal cells, and tumor cells interact within disease microenvironments. Spatial biology platforms provide this information, helping researchers identify biomarkers and treatment-response mechanisms that may not be visible through conventional sequencing approaches. Company investments in reagent manufacturing and platform expansion indicate expectations of continued pharmaceutical demand. Pharmaceutical research spending increasingly favors spatially resolved multiomic datasets.
Growth of large-scale human cell atlas initiatives constitutes another significant growth driver. National and international atlas projects are producing spatially resolved maps of human tissues, organs, and disease states. Programs such as BICAN and HuBMAP are generating thousands of datasets spanning multiple organs and donors. These initiatives require high-throughput sequencing, advanced imaging systems, computational infrastructure, and long-term data management capabilities. The resulting datasets also create secondary demand from researchers seeking reference materials for comparative studies. HuBMAP has generated 5,032 datasets across 27 organ classes, with 310 donors represented in portal datasets, creating substantial spatial data generation needs.
The rising importance of oncology biomarker development is accelerating adoption of spatial technologies. Cancer remains one of the strongest commercial use cases for spatial technologies because tumor biology is highly dependent on tissue context. Drug developers increasingly seek biomarkers that reveal immune-cell localization, tumor heterogeneity, and treatment-response pathways. Spatial transcriptomics and multiplex imaging provide information that supports patient selection and translational research efforts. Investments by platform providers in multiomic workflows reflect the increasing role of oncology research as a purchasing driver. The growing prevalence of cancer and the need for accurate treatment models are fueling demand for spatial analysis.
Integration of transcriptomics, genomics, and proteomics workflows is expanding the addressable market for spatial platforms. Research organizations are moving away from standalone analytical methods and toward multiomic approaches that combine several molecular layers. Spatial biology platforms increasingly integrate RNA, DNA, and protein measurements within a single workflow. The commercial advantage lies in reducing experimental fragmentation while generating richer datasets. Suppliers are responding through partnerships, acquisitions, and platform integration strategies designed to capture larger portions of research spending.
Advances in computational biology and artificial intelligence are increasing the utility of spatial datasets. The value of spatial biology depends heavily on data interpretation. Improvements in machine learning, image analysis, and multimodal data integration are increasing the utility of spatial datasets. Research activity demonstrates growing efforts to build foundation models and analytical frameworks capable of extracting biological insight from increasingly complex datasets. As analytical capabilities improve, the return on investment from spatial experiments becomes more attractive to pharmaceutical and academic buyers. Over 1,500 spatial datasets are available through HuBMAP visualization tools, reinforcing demand for software and interpretation platforms.

Market Restraints

High instrument and workflow costs create budget constraints for academic and smaller research organizations. Spatial genomics and transcriptomics platforms typically require substantial capital investment. Beyond instrument acquisition, laboratories must purchase specialized reagents, sequencing capacity, software licenses, data storage infrastructure, and analytical support. Budget constraints within academic institutions and fluctuations in research funding can delay purchasing decisions. Evidence from industry participants shows that capital expenditure pressure remains a challenge for parts of the customer base.
Complexity of data interpretation limits adoption and increases reliance on specialized expertise. Generating spatial data is no longer the primary challenge for many laboratories. Interpreting high-dimensional datasets often requires expertise in bioinformatics, image analysis, computational biology, and statistics. Workforce shortages in these areas can slow adoption. The complexity increases further when genomic, transcriptomic, and proteomic data are combined within a single workflow.
Lack of workflow standardization complicates cross-study comparisons and validation. The market currently includes multiple technology approaches, including sequencing-based, probe-based, imaging-based, and in-situ hybridization platforms. Differences in sample preparation, spatial resolution, throughput, and analytical pipelines can complicate comparisons across studies. This fragmentation increases validation requirements and may slow adoption in regulated environments.
Lengthy path from research use to clinical deployment extends commercialization timelines. Most spatial genomics and transcriptomics technologies remain concentrated in research settings. Clinical adoption requires analytical validation, regulatory review, reproducibility testing, and demonstration of clinical utility. These processes can extend commercialization timelines and increase development costs. The challenge is particularly relevant for suppliers seeking expansion into diagnostic applications.
Intellectual property and technology competition create uncertainty for emerging suppliers. The sector has experienced substantial intellectual-property activity as companies seek to protect assay chemistry, imaging technologies, and analytical methods. Patent disputes and licensing requirements can increase operating costs and create uncertainty for emerging suppliers. Larger companies with established patent portfolios may possess advantages in commercializing new technologies.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated spatial biology ecosystems, multiomic workflows, and AI-driven data interpretation. The Oncology Application segment represents the most commercially important category because cancer research depends heavily on understanding cellular heterogeneity, immune infiltration patterns, treatment resistance mechanisms, and tumor microenvironment dynamics. Many of these biological processes cannot be adequately characterized when tissue architecture is lost during sample preparation. Pharmaceutical and biotechnology companies constitute the most influential buyers within this segment, with purchasing decisions increasingly focusing on assay sensitivity, multiplexing capability, spatial resolution, workflow scalability, and compatibility with existing sequencing infrastructure.
Competition within oncology-oriented spatial biology increasingly extends beyond instrument performance. Suppliers compete through integrated workflows, software capabilities, reagent portfolios, and service support. Companies able to provide end-to-end solutions, from tissue preparation through computational interpretation, are positioned more favorably than suppliers offering isolated technologies. The segment's performance has broader market implications because oncology programs often command larger research budgets and generate recurring consumable demand.
The Spatial Transcriptomics type segment, including Sequencing-Based, Probe-Based, and Imaging-Based approaches, is expanding as researchers seek to understand gene expression in tissue context. Spatial Genomics, including In-Situ Hybridization and Next-Generation Sequencing, enables DNA-level analysis within tissue architecture. The integration of multiple spatial modalities is becoming increasingly important for comprehensive biological insight.
The Academic and Research Institutes end-user segment represents a substantial customer base, while Pharmaceutical and Biotech Companies are the principal source of demand generation for translational and drug discovery applications. The Neurology, Immunology, and Developmental Biology application segments are growing as spatial methods expand beyond oncology. The integration of consumables, software, and data analysis services is gaining importance alongside instruments as suppliers build broader ecosystems rather than competing solely on instrument performance.

Competitive and Strategic Outlook

The competitive landscape is characterized by a technology-driven environment moving toward broader platform competition, with suppliers increasingly competing through integrated ecosystems that combine instruments, consumables, software, cloud analytics, and service offerings. 10x Genomics maintains a strong position through its spatial and single-cell technology portfolio, while Illumina, Inc. benefits from its established sequencing infrastructure and customer relationships. Bruker Spatial Biology, Inc. has expanded its position through the integration of NanoString and other spatial assets, creating a broader portfolio spanning transcriptomics, genomics, proteomics, software, and services. Akoya Biosciences continues investing in manufacturing capacity and multiomic workflows. Other notable participants include Bio-Techne, Standard BioTools, Vizgen Inc., Agilent Technologies, Inc., Velsera, and S2 Genomics, Inc.
Competitive differentiation increasingly depends on ecosystem breadth rather than individual platform specifications. Barriers to entry are increasing because successful commercialization now requires expertise across molecular biology, imaging, software engineering, bioinformatics, and regulatory compliance. Consumable pull-through, proprietary chemistry, installed instrument bases, and analytical software ecosystems create switching costs that favor established suppliers.
Recent key developments highlight the industry's focus on whole-transcriptome platforms, single-cell resolution, and AI-driven analysis. Illumina launched the StrataMap Spatial Solution, an end-to-end spatial transcriptomics platform delivering whole-transcriptome profiling at single-cell resolution. 10x Genomics introduced Atera, a next-generation spatial biology platform providing whole-transcriptome in situ analysis with single-cell sensitivity. Bioptimus launched STELA, a clinically linked spatial biology atlas developed with 10x Genomics and Broad Clinical Labs. Stellaromics launched Pyxa, the first commercial platform enabling multiplexed 3D spatial transcriptomics in intact tissues. Illumina introduced its first spatial transcriptomics technology program, enabling unbiased whole-transcriptome profiling with cellular resolution.
North America represents the most mature commercial environment due to extensive biomedical research funding and established sequencing infrastructure. European demand is supported by translational research programs and precision medicine initiatives. Asia Pacific is becoming an increasingly important growth region due to expanding biotechnology sectors and rising genomics investment. The Middle East and Africa are expanding through government-supported healthcare modernization programs.

Short Conclusion

The spatial genomics and transcriptomics market is positioned for robust growth driven by the convergence of pharmaceutical R&D investment, atlas initiatives, and computational biology advances. The transition from bulk and single-cell sequencing toward spatially resolved multiomic analysis represents a fundamental shift in tissue-level disease characterization. While challenges related to cost, data complexity, and workflow standardization persist, strategic investments in integrated ecosystems, multiomic workflows, and AI-driven analysis are creating sustainable competitive advantages for established suppliers. The long-term market outlook remains positive, with spatial genomics and transcriptomics evolving as a strategic component within translational research, biomarker discovery, and precision medicine development, supporting improved target identification, patient stratification, and drug-response prediction across global life science research.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET BY TYPE

5.1. Introduction
5.2. Spatial Genomics
- 5.2.1. In-Situ Hybridization
- 5.2.2. Next-Generation Sequencing
- 5.2.3. Others
5.3. Spatial Transcriptomics
- 5.3.1. Sequencing-Based
- 5.3.2. Probe-Based
- 5.3.3. Imaging-Based

6. SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET BY APPLICATION

6.1. Introduction
6.2. Neurology
6.3. Oncology
6.4. Immunology
6.5. Developmental Biology
6.6. Others

7. SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET BY END-USER

7.1. Introduction
7.2. Pharmaceutical and Biotech Companies
7.3. Academic and Research Institutes
7.4. Others

8. SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others